Biointron’s Q4 2025 antibody industry report aims to explore the events and trends of the biopharmaceutical industry in October, November, and December. This quarter, 5 novel monoclonal antibody drugs have been approved by the US, UK, and China.
- Trastuzumab Botidotin
- Sibeprenlimab (Voyxact)
- Picankibart (Pecondle)
- Depemokimab (Exdensur)
- Narsoplimab (Yartemlea)
Q4 2025 saw various acquisitions, collaborations, and licensing agreements of up to USD$12 billion. Investment into antibody drug startups has focused on de novo proteins and bispecific ADCs.
Gain exclusive insights into current trends such as:
- 5 novel antibody drugs approved for the first time in Q4
- Top 20 antibody drug deals, including acquisitions, licensing agreements, and collaborations of up to US$12B
- Current research into antibody conjugate types: ADCs, ABCs, ISACs, ARCs, and ATCs
- The landscape of psoriasis treatment
- A list of antibody drugs with soon approaching approval action dates to keep an eye out for in Q1 2026